The Primary Sclerosing Cholangitis Market is estimated to be valued at US$ 3,604.7 Mn in 2022 and is expected to exhibit a CAGR of 4.6% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.

SWOT Analysis:-

·         Strengths: Growing research and development activities for improved treatment options.

·         Weaknesses: No FDA approved drug offers cure and existing medications only manage symptoms.

·         Opportunities: High unmet need in the market provides scope for novel drugs and combination therapies.

·         Threats: Stringent regulations for drug approval and high costs associated with clinical trials.

Key Takeaways:-

The Global Primary Sclerosing Cholangitis Market Growth is expected to witness high, exhibiting CAGR of 4.6% over the forecast period, due to increasing research in developing novel drugs for PSC.

The global PSC market size in 2022 is estimated to be US$ 3,604.7 Mn. North America dominates the global PSC market currently due to growing prevalence of IBD in the region and availability of advanced healthcare facilities.

Regional analysis:

North America leads with the highest market share currently due to growing prevalence of IBD disorders leading to PSC in the region along with availability of advanced healthcare facilities. The Asia Pacific region is anticipated to exhibit fastest growth over the forecast period owing to rising healthcare expenditure and increased awareness regarding PSC.

Key players:

Key players operating in the Primary Sclerosing Cholangitis market are Mirum Pharmaceuticals, Intercept Pharmaceuticals, CymaBay Therapeutics, Dr. Falk Pharma GmbH, and Gilead Sciences.

Read More -  https://www.newsstatix.com/primary-sclerosing-cholangitis-market-growth-and-outloook-analysis/